Endometrial stromal sarcoma in a 29-year-old patient. Case report and review of the literature

Objective: Endometrial stromal sarcomas are rare tumors accounting for about 0.2% of all genital tract malignancies. They are considered to occur more often in premenopausal women. Endometrial stromal sarcomas are hormone sensitive tumors. A state of hyper-estrogenemia could act as a growth stimulus. Given the rarity of these tumors there are limited reports in the literature referring to the clinical management and final outcome of these cases. Case: The patient, a 29-year-old woman, had a surgical history of myomectomy in another hospital three months before her referal to our department. The histological examination of the removed myoma showed an endometrial stromal sarcoma. Total abdominal hysterectomy, with bilateral salpingo-oophorectomy, omentectomy and elective pelvic lymphadenectomy were then performed as a second radical surgical approach. Conclusion: Endometrial stromal sarcomas are uncommon and their differential diagnosis from typical submucosal uterine myomas or benign endometrial polyps could be difficult. The hysteroscopic features of uterine sarcomas are often similar to those of endometrial polyps or submucosal myomas. The histological examination of the specimen is necessary to exclude malignancy and establish the final diagnosis. Total abdominal hysterectomy, bilateral salpingo-oopherectomy with pelvic lymphadenectomy is the optimal treatment in cases of endometrial stromal sarcomas.

Endometrial sarcoma; Leiomyoma; Myomectomy

[1] Koss L.G., Brunschwig A.: “Endometrial stromal sarcoma”. Surg. Gynecol. Obstet., 1965, 121, 531.

[2] Evans H.L.: “Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma”. Cancer, 1982, 50, 2170.

[3] Boardam C.H., Webb M.J., Jefferies J.A.: “Low grade endometrial sarcoma in the Ectocervix after therapy for breast cancer”. Gynecol. Oncol., 2009, 79, 120.

[4] Pink D., Lindnes T., Mrozek A., Kretzschmas A., Thuss Patient P.C., Dorken B., Peter Reicharct Hasm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature”. Gynecol. Oncol., 2006, 101, 464.

[5] Mesia A.F., Demopoulos I.: “Effects of leuprolide acetate on low grade endometrial stromal sarcoma”. Am. J. Obstet. Gynecol., 2000, 182, 1140.

[6] Husseiny G.B., Bareedy N.A., Mourad W.A., Mohamed G., Shoukr M., Subhi J.: “Prognostic factors and treatment modalities in uterine sarcoma”. Am. J. Clin. Oncol., 2002, 25, 256.

[7] Pekindil G., Tuncyurek O., Orguc S., Inceboz U., Kandiloglu A.R., Caglas H.: “A case of endometrial stromal sarcoma with curvilinear calcification”. Gynecol. Oncol., 2005, 98, 318.

[8] Horn L.C., Schmidt D., Fathke C., Ulrich U.: “New FIGO staging for uterine sarcomas”. Pathol., 2009, 30, 302 (in German).

[9] Prat J.: “FIGO staging for uterine sarcomas”. Int. J. Gynaecol. Obstet., 2009, 104, 177. Erratum in Int. J. Gynaecol. Obstet., 2009, 106, 277.

[10] Pekindil G., Tuncyurek O., Orguc S., Inceboz U., Kandiloglu A.R., Caglas H.: “A case of endometrial stromal sarcoma with curvilinear calcification”. Gynecol. Oncol., 2005, 98, 318.

[11] Kempson R.L., Bari W.: “Uterine sarcomas. Classification diagnosis and prognosis”. Hum. Pathol., 1970, 1, 331.

[12] Berek J.S., Apashi E.Y., Hillard P.A. (eds.). Novak’s Gynecology. Baltimore, Williams & Wilkins, 1996.

[13] Ashraf-Ganjoei T., Behtash N., Shariat M., Mosavi A.: “Lowgrade endometrial stromal sarcoma of uterine corpus, a clinicpathological and survey study in 14 cases”. World J. Surg. Oncol., 2006, 4, 50.

[14] Pekindil G., Tuncyureko O., Orcuc S., Inceboz U., Kandiloglu A.R., Gaglar H.: “A case calcification”. Gynecol. Oncol., 2005, 98, 318.

[15] Fan L., Guo D., Ma T., Wu W. Zhonghua Bing Li Xue Za Zhi, 2000, 29, 432.

[16] Taina E., Maenpaa J., Erkkola R., Ikkada J., Soderstrom O., Viitanen A.: “Endometrial stromal sarcoma: A report of nine cases”. Gynecol. Oncol., 1989, 32, 156.

[17] Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., Lewis J.I.: “Treatment of endometrial stromal tumors”. Gynecol. Oncol., 1990, 36, 60.

[18] Bonder K., Bonder Alder B., Obermais A., Windbichler G., Petru E., Mayerhofes K.: “Prognostic parameters in endometrial stromal sarcoma: a clinicopathological study in 31 patients”. Gynecol. Oncol., 2001, 81, 160.

[19] Kohanpaa K.V., Wahlstrom T., Grohn P., Heinonen E., Nieminen U., Widholm O.: “Sarcoma of the uterus: a clinicopathologic study of 119 patients”. Obstet. Gynecol., 1989, 67, 417.

[20] Ramondetta L., Boduska D., Deavers M., Jhingran A.: “Uterine Sarcomas”. In: M.D. Anderson Cancer Care Series, Gynecologic Cancer. Eifel P.J., Gershenson D.M., Kavanagh J.J., Wa E.G. (eds.). New York, Springer, 2006, 125.

[21] “Clinical study investigating the idea of lymphadenectomy, surgical castration and adjuvant hormonal therapy in endometrial stromal sarcoma”. Brit. J. Cancer, 2007, 97, 1194.

[22] Reich O., Winter R., Regauer S.: “Should lymphadenectomy be perfomed in patients wih endometrial stromal sarcoma?”. Gynecol. Oncol., 2003, 97, 82.

[23] Ihnen M., Mahner S., Janicke F., Scharz J.: “Current treatment options in uterine endometrial stromal sarcoma: Report of a case and review of the literature”. Int. J. Gynecol. Cancer, 2007, 17, 957.

[24] Gellera M.A., Argentaa P., Bradley W., Dusenkeryb K.E., Brookera D., Down L.S. et al.: “Treatment and recurrence patters in endometrial stromal sarcomas and the relation to c-kit expression”. Gynecol. Oncol., 2004, 95, 632.

[25] Wetrmann H.D., Knocke T.H., Kurea H., Potter R.: “Radiation therapy in the treatment of endometrial stromal sarcomas”. Int. J. Ratiat., 2005, 96, 402.

[26] Reich O., Reganer S., Urdl W., Lahousen M., Winter R.: “Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas”. Br. J. Cancer, 2000, 82, 1030.

[27] Reich O., Reganer S.: “Hormonal therapy of endometrial stromal sarcoma”. Corr. Opin. Oncol., 2007, 19, 347.

[28] Pekindil G., Tuncyurek O., Orguc S., Inceboz U., Kandiloglu A.R., Caglas H.: “A case of endometrial stromal sarcoma with curvilinear calcification”. Gynecol. Oncol., 2005, 98, 318.

[29] Mesia A.F., Demopoulos I.: “Effects of leuprolide acetate on low grade endometrial stromal sarcoma”. Am. J. Obstet. Gynecol., 2000, 182, 1140.

[30] Scribner D.R. Jr., Walker Jr.: “Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace”. Gynecol. Oncol., 1998, 71, 458.

[31] Burke C., Hickey K.: “Tretment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue”. Obstet. Gynecol., 2004, 104, 1182.

[32] Rovirosa A., Ascaso C., Ordi J., Abellana R., Arenas M., Lejarcequi J.A. et al.: “Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages”. Int. J. Rad. Oncol. Biol. Phys., 2002, 52, 1320.

[33] Nardal R.R., Kjoerstad K., Stenwing A.E., Trope C.T.: “Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus: a survey of patients treated at the norvegian Radium Hospital 1971-1985”. Int. Gynecol. Cancer, 1993, 3, 110.

[34] Liokumovich P., Goldberg I., Davidson B., Gotlieb W.H., Zahavi T., Ben-Baruch G. et al.: “Expression of metalloproteinases endometrial stromal sarcoma: immunhistochemical study using image analysis”. J. Clin. Pathol., 1999, 52, 198.

[35] Bonder K., Bonder Alder B., Obermais A., Windbichler G., Petru E., Mayerhofes K.: “Prognostic parameters in endometrial stromal sarcoma: a clinicopathological study in 31 patients”. Gynecol. Oncol., 2001, 81, 160.